Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...

Personalized medicine market growth PORTLAND, OR, UNITED STATES, August 11, 2025 /EINPresswire / -- The global personalized medicine market , ...

REGENXBIO Inc. announced it will initiate a pivotal phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal ...

The global cosmetic surgery market size was US$ 65.3 billion in 2021. The global cosmetic surgery market is expected to grow to US$ 165.0 billion by 2030 by registering a compound annual growth rate ...

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epco ...